에 대한 최신 뉴스 DarioHealth (NASDAQ:DRIO) 주식

DarioHealth

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

DarioHealth Corp

RBC Capital analyst Scott Hanold reiterates Tamboran Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBN#NYSE">TBN</a>) with a Sector Perform and maintains $31 price target.

News

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Sector Perform on Tamboran Resources, Maintains $31 Price Target

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) said on Thursday that it is significantly expanding its wellness offerings, with plans to introduce over 2,000 new items across a variety of categories, including <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42893497/target-is-expanding-its-wellness-assortment-with-2-000-new-items-more-than-half-under-10" rel="noreferrer noopener">more than 600 exclusive products.</a>
This expansion reflects Target&#8217;s strategy&nbsp;of making wellness products more accessible and affordable, with over half of the new items priced under $10, the company said in a press release.
The company&#8217;s integrated approach spans multiple areas of wellness, from beauty and personal care to nutrition, food, and wellness technology, ensuring that consumers can curate a personalized wellness regimen.
Target&#8217;s new assortment includes emerging brands and exclusive partnerships.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/01/42894683/los-angeles-wildfires-stoke-investor-fears-edison-internationals-stock-ended-10-lower-on-wednesday-amid-concerns-over-possible-equipment-links-to-forest-fires" rel="noreferrer noopener">Los Angeles Wildfires Stoke Investor Fears: Edison International&#8217;s Stock Ended 10% Lower On Wednesday Amid Concerns Over Possible Equipment Links To Forest Fires</a>
In the beverage category, the retailer is introducing non-alcoholic beverages like BERO, a premium beer co-founded by actor Tom Holland. Target is also expanding its beauty and self-care offerings, with new haircare lines from Ashley Tisdale&#8216;s Being Frenshe and Blake Lively&#8216;s Blake Brown, as well as wellness gummies from Kourtney Kardashian Barker&#8216;s Lemme brand.
Additionally, Target is enhancing its men&#8217;s wellness selection with products from Dr. Squatch and Dwayne &#8220;The Rock&#8221; Johnson&#8216;s Papatui line, along with expanding its wellness technology category, introducing innovative items like SLF&#8217;s infrared red light therapy mask and Therabody&#8217;s SmartGoggles.
Target is also adding new activewear, loungewear, and sleepwear options to cater to growing wellness and self-care trends. The expanded wellness range will be available in 2025, allowing consumers to support their well-being while staying within their budget.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, TGT stock has lost over 3% in the past year. Investors can gain exposure to the stock via&nbsp;VanEck Retail ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTH#NASDAQ">RTH</a>).
Price Action: TGT shares closed lower by 0.74% to $138.22 on Wednesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/42890191/trump-themed-nfts-launch-on-bitcoin-network-for-first-timeheres-what-you-should-know" target="_blank" rel="noreferrer noopener">Trump-Themed NFTs Debut On Bitcoin Network — One Card Gets Listed At $1.9 Million</a></li>
</ul>
Photo courtesy: Shutterstock.

Equities

Markets

General

Merrill Lynch Retail HOLDRS Trust due 12/31/41

Target's Wellness Push: Over 50% Of New Items Priced Under $10

RBC Capital analyst Ashish Sabadra reiterates Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and maintains $95 price target.

NDAQ

RBC Capital Reiterates Outperform on Nasdaq, Maintains $95 Price Target

Scotiabank analyst Orest Wowkodaw maintains Ivanhoe Mines (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IVN#TSX">IVN</a>) with a Sector Outperform and lowers the price target from C$21 to C$20.

TSX:IVN

Scotiabank Maintains Sector Outperform on Ivanhoe Mines, Lowers Price Target to C$20

The Federal Reserve indicated a more tempered approach to <a href="https://www.benzinga.com/25/01/42886101/investors-should-expect-no-rate-cuts-in-q1-2025-after-federal-reserves-december-minutes-release-strategist-says">interest rate cuts in 2025</a>.
That&#8217;s according to minutes from the Fed&#8217;s December meeting, which were released on Wednesday, Jan. 8. 
Investor interest shifted toward treasury bonds, as the 10-year yield briefly touched 4.73% on Wednesday, amid resurfacing inflation fears and anticipation around potential tariffs and tax policies. 
Fixed-income exchange-traded funds (ETFs) can help investors get exposure to bonds. This is thanks to the stability and predictable income opportunity amid equity market volatility that they hold.
Here are three standout ETFs poised to benefit:
<ul>
<li>iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LQD#NYSE">LQD</a>) offers diversified exposure to investment-grade corporate bonds, which are less likely to default during economic uncertainty. The ETF boasts a weighted average maturity of 12.94 years but includes bonds with varying maturities to balance risk. Its 30-day SEC yield is 5.4%, and its expense ratio is 0.14%, making it a cost-effective option.</li>
</ul>
<ul>
<li>Vanguard Short-Term Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSV#NYSE">BSV</a>) is designed for stability and focuses on short-duration U.S. Treasury and investment-grade corporate bonds, with an average maturity of just 2.8 years. Music to the ears for risk-averse investors looking to shield themselves from rate volatility. The fund&#8217;s 30-day SEC yield is approximately 4.4%, with minimal sensitivity to interest rate changes. A low expense ratio of 0.04% makes it even more attractive.</li>
</ul>
<ul>
<li>Vanguard Total Bond Market ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BND#NASDAQ">BND</a>) offers comprehensive exposure to the entire U.S. bond market, including Treasuries, mortgage-backed securities, and investment-grade corporate bonds. The ETF's 30-day SEC yield stands at 4.55%, providing a steady income stream. An expense ratio of 0.03% is another point to note. Additionally, the ETF's liquidity and resilience during past crises, such as the 2020 pandemic sell-off, makes it a reliable long-term investment choice.</li>
</ul>
<h3 class="wp-block-heading">Why Bond Funds?</h3>
The Fed's cautious message supports a longer-term case for bond ETFs. 
Short-duration bond ETFs are less sensitive to rate fluctuations and can offer better returns than cash or savings accounts while limiting interest rate risk.
Similarly, investment-grade corporate bond ETFs are a sweet spot for yield-seeking investors. These ETFs balance risk and reward by offering exposure to highly rated corporate debt that typically performs well in uncertain economic conditions.
These apart, ultra-short bond ETFs like the iShares 0-3 Month Treasury Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGOV#NYSE">SGOV</a>) could also gain traction as cash alternatives.
See Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/01/42895976/china-focused-etfs-face-uncertainty-as-us-blacklists-tencent-catl">China-Focused ETFs Face Uncertainty As US Blacklists Tencent, CATL</a></li>
</ul>
Photo via Shutterstock

Specialty ETFs

ETFs

SGOV

Fed's Cautious Rate Cut Approach Boosts Appeal Of These 3 ETFs

Barclays analyst Seth Sigman maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Overweight and raises the price target from $90 to $98.

Barclays Maintains Overweight on Walmart, Raises Price Target to $98

Osisko Gold Royalties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OR#NYSE">OR</a>) has outperformed the market over the past 5 years by 2.49% on an annualized basis producing an average annual return of 14.97%. Currently, Osisko Gold Royalties has a market capitalization of $3.47 billion. 
Buying $100 In OR: If an investor had bought $100 of OR stock 5 years ago, it would be worth $203.50 today based on a price of $18.60 for OR at the time of writing.
<h3>Osisko Gold Royalties's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736436616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Osisko Gold Royalties 5 Years Ago Would Be Worth This Much Today

Barclays analyst Seth Sigman maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Equal-Weight and raises the price target from $1088 to $1110.

ORLY

Barclays Maintains Equal-Weight on O'Reilly Automotive, Raises Price Target to $1110

RBC Capital analyst Gregory Renza maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Outperform and lowers the price target from $68 to $48.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

RBC Capital Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $48

Barclays analyst Karen Short maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Overweight and lowers the price target from $102 to $100.

Barclays Maintains Overweight on Dollar Gen, Lowers Price Target to $100

Barclays analyst Seth Sigman maintains Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) with a Equal-Weight and lowers the price target from $8 to $7.

BYON

Barclays Maintains Equal-Weight on Beyond, Lowers Price Target to $7

Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) owned search giant Google is the latest tech company to donate to Donald Trump's inauguration fund ahead of the highly anticipated<a href="https://www.benzinga.com/25/01/42801809/apple-ceo-tim-cook-reportedly-donates-1-million-to-trump-inauguration-joins-ranks-of-mark-zuckerberg-jeff-bezos-and-sam-altman"> Jan. 20 event.</a>
What Happened: Google announced a $1 million donation to Trump's inauguration,<a href="https://www.benzinga.com/general/politics/24/07/39826475/trumps-new-running-mate-j-d-vance-wants-to-break-up-google-could-2024-election-be-bad-for-big-te"> joining the ranks</a> of Meta Platforms, Amazon.com, Ford Motor Company and more.
Several tech billionaires including Apple CEO Tim Cook and OpenAI CEO Sam Altman have also announced $1 million donations on their own and not directly from their associated companies.
The donation by Google made on Monday was confirmed by <a href="https://www.politico.com/live-updates/2025/01/09/congress/google-donation-donald-trump-inauguration-00197233">Politico </a>on Thursday and comes as Alphabet CEO Sundar Pichai was among the tech moguls who met with Trump at Mar-A-Lago since his 2024 presidential election win.
"Google is pleased to support the 2025 inauguration, with a livestream on YouTube and a direct link on our homepage. We're also donating to the inaugural committee," Google's global head of government affairs and public policy Karen Bhatia told Politico.
Google previously donated $285,000 to the 2016 and 2020 inaugurations, a spokesperson told Politico. Google also previously promoted the inauguration on its homepage and YouTube.
Read Also: <a href="https://www.benzinga.com/24/12/42660866/trump-gets-ford-vehicles-1m-for-inauguration-will-musk-respond-or-could-he-ride-in-rival-vehicle">Trump Gets Ford Vehicles, $1M For Inauguration &#8211; Will Musk Respond Or Could He Ride In Rival Vehicle?</a>
Why It's Important: The donation from Google comes as the company has been targeted by the Department of Justice for <a href="https://www.benzinga.com/tech/24/11/42140450/doj-targets-google-chrome-poll-shows-64-oppose-alphabet-breakup-youtube-seen-as-top-prize">alleged monopolistic behavior </a>and could be forced to break up and spinoff assets like the Chrome browser.
While there's no certainty that a donation or a visit to Mar-A-Lago will sway the new administration or prevent such outcomes, changes to the DOJ&#8217;s leadership could potentially shift the company&#8217;s legal challenges.
Incoming Vice President J.D. Vance also previously said he <a href="https://www.benzinga.com/general/politics/24/07/39826475/trumps-new-running-mate-j-d-vance-wants-to-break-up-google-could-2024-election-be-bad-for-big-te">wants to break up </a>Google, which could make the company a target of the new administration.
Senator Ted Cruz (R-Texas) recently told Politico that Republicans would target Google's content moderation policies on the search engine and on YouTube.
GOOG Price Action: Alphabet stock closed at $195.39 Wednesday versus a 52-week trading range of $131.55 to $202.88. Alphabet stock is up 37% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/25/01/42880549/nvidia-ceo-jensen-huang-wants-to-congratulate-trump-at-mar-a-lago-but-hasnt-been-invited-yet">Nvidia CEO Jensen Huang Wants To Congratulate Trump At Mar-A-Lago, But Hasn&#8217;t Been Invited Yet</a></li>
</ul>
Photo: Shutterstock

Politics

Tech

GOOG

GOOGL

Google Donates $1 Million To Trump Inauguration, Plans YouTube Livestream: 'Pleased To Support'

RBC Capital analyst Daniel Perlin reiterates Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) with a Outperform and maintains $25 price target.

FLYW

RBC Capital Reiterates Outperform on Flywire, Maintains $25 Price Target

Barclays analyst Seth Sigman maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Equal-Weight and lowers the price target from $95 to $89.

Barclays Maintains Equal-Weight on Best Buy Co, Lowers Price Target to $89

RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) with a Outperform and maintains $31 price target.

CTNM

RBC Capital Reiterates Outperform on Contineum Therapeutics, Maintains $31 Price Target

Barclays analyst Matthew McClintock maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Overweight and raises the price target from $3024 to $3585.

Barclays Maintains Overweight on AutoZone, Raises Price Target to $3585

Barclays analyst Seth Sigman maintains Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Equal-Weight and lowers the price target from $66 to $54.

Barclays Maintains Equal-Weight on Advance Auto Parts, Lowers Price Target to $54

RBC Capital analyst Steven Shemesh reiterates Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Outperform and maintains $22 price target.

RBC Capital Reiterates Outperform on Albertsons Companies, Maintains $22 Price Target

RBC Capital analyst Sam Crittenden reiterates Capstone Copper (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CS#TSX">CS</a>) with a Outperform and maintains C$12 price target.

TSX:CS

RBC Capital Reiterates Outperform on Capstone Copper, Maintains C$12 Price Target

Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) has outperformed the market over the past 5 years by 7.91% on an annualized basis producing an average annual return of 20.39%. Currently, Unum Gr has a market capitalization of $13.32 billion. 
Buying $1000 In UNM: If an investor had bought $1000 of UNM stock 5 years ago, it would be worth $2,512.92 today based on a price of $72.95 for UNM at the time of writing.
<h3>Unum Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736435709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Unum Gr 5 Years Ago Would Be Worth This Much Today

DarioHealth Corp. (DRIO) Q2 2024 Earnings Call Transcript

DarioHealth (DRIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Rhyee from TD Co...

DarioHealth Buy Rating Affirmed: Strategic Growth and Path to Profitability

Dario signs new regional health plan

DarioHealth (DRIO) announced a new collaboration with a pharma company that will utilize Dario Connect among their patient populations to further t...

DarioHealth announces new collaboration with pharma company

DarioHealth GAAP EPS of $0.25 beats by $0.52, revenue of $7.42M beats by $0.02M

Reports Q3 revenue $7.42M, consensus $7.4M. "Our third quarter included strong execution of our multi-year strategic plan of being a profitable pro...

DarioHealth reports Q3 EPS (25c), consensus (27c)

DarioHealth ( ($DRIO) ) has released its Q3 earnings. Here is a breakdown of the information DarioHealth presented to its investors. DarioHealth Co...

DarioHealth Earnings Reflect Growth Amid Challenges

DarioHealth Corp. (DRIO) Q3 2024 Earnings Call Transcript

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on DarioHealth (DRIO – Research Report). The associated price target was lowered...

Positive Outlook for DarioHealth Driven by B2B2C Growth and Strategic Partnerships

DarioHealth (DRIO) announced the signing of four contracts with self-insured employers that are expected to go live in the first quarter of 2025. D...

Comments

DarioHealth

뉴스

에 대한 최신 뉴스 DarioHealth (NASDAQ:DRIO) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌